|
Originally published In Press as doi:10.1074/jbc.M102916200 on April 25, 2001
J. Biol. Chem., Vol. 276, Issue 31, 29410-29419, August 3, 2001
Kidney Androgen-regulated
Protein Interacts with Cyclophilin B and Reduces Cyclosporine
A-mediated Toxicity in Proximal Tubule Cells*
Cristina
Cebrián ,
Cristina
Aresté ,
Antoni
Nicolás ,
Pere
Olivé ,
Ana
Carceller§,
Jaume
Piulats§, and
Anna
Meseguer ¶
From the Centre d'Investigacions en Bioquímica i
Biologia Molecular, Hospital Universitari Vall d'Hebron, Pg. Vall
d'Hebron 119-129, Plta. 14, 08035 Barcelona, Spain and the
§ Laboratorio de Bioinvestigación, Merck Farma y
Química, S.A., 08010 Barcelona, Spain
Received for publication, April 3, 2001, and in revised form, April 25, 2001
 |
ABSTRACT |
The gene for kidney androgen-regulated
protein (KAP) is the most abundant and specific gene expressed in mouse
kidney proximal tubule cells, where it is tightly regulated by steroid
and thyroid hormones in different tubule segments. Despite the
cell-specific expression, strict regulatory mechanisms, and relative
abundance, nothing is known of the function of its encoded protein,
which does not exhibit known structural or functional domains, or
homologies with other sequences in the data bases. We raised monoclonal
antibodies against KAP, which specifically recognize a protein with an
apparent molecular mass of 20 kDa in crude kidney homogenates,
the distribution and regulation of which parallel that of its mRNA.
To gain insight into its function, we performed a yeast two hybrid
screen and determined that KAP specifically interacts with
cyclophilin B. Furthermore, cyclosporine A (CsA)-treated mice exhibited
a significant decrease in KAP levels, and tetracycline-controlled
overexpression of KAP in stably transfected proximal tubule cells
significantly decreased the toxic effects of CsA. Taken
together, these results indicate a functional relationship among
KAP-, cyclophilin B-, and CsA-mediated nephrotoxicity and
suggest an important role of KAP in renal physiology, providing new
data on the molecular mechanisms implied in the toxic effects of
CsA.
 |
INTRODUCTION |
The kidney androgen-regulated protein
(KAP)1 was identified as an
abundant 20,000-dalton protein by in vitro translation of male mouse kidney mRNA (1). Shortly after its identification, it
became a useful model for studying kidney-specific hormonal regulation
of gene expression. The KAP gene exhibits
androgen-dependent and -independent regulatory mechanisms
in different segments of proximal tubules (2). Whereas a functional
androgen receptor and testosterone are required for expression in
cortical S1 and S2 segments of proximal tubules, no androgen is
required for expression in the medullar S3 segment (3, 4). Therefore,
females, castrated males, and androgen receptor-deficient Tfm/Y males
express the gene in S3 cells exclusively, whereas males and
androgen-induced females also express the gene in S1/S2 cells. KAP
mRNA expression in S3 cells depends on thyroid hormone (5) and can
be further induced by estrogens in females (6).
Estrogen-dependent expression of the KAP gene in rat and
mouse uteri around delivery has also been reported (7, 8). This complex
regulation of KAP is actually more sophisticated because it has
also been determined that both thyroid hormone (9) and the
growth hormone/insulin-like growth factor-1 (GH/IGF-1)
axis2 cooperate with
androgens in promoting KAP gene expression in S1/S2 cells.
KAP constitutes the most abundant and specific gene expressed in
proximal renal tubule cells, as shown by serial analysis of gene
expression (10), serial analysis of differential expression (11), and expression profiling of active genes (12). Cell specificity
and the complex regulatory mechanisms involved in KAP mRNA
expression, together with KAP mRNA relative abundance, point to an
important role for its encoded protein.
Analyses of both nucleotide and peptide sequences have failed to reveal
significant homology with other genes, expressed sequence tags,
or proteins or with known structural or functional domains. The absence
of known functional domains has greatly reduced experimental approaches
to elucidating KAP function and prompted us to perform a yeast two
hybrid assay. The present work shows that KAP interacts with the
CsA-binding protein CyPB, that CsA administration reduces KAP
steady-state levels in mouse kidney, and that KAP overexpression reduces CsA toxicity in cultured proximal tubule cells. Thus, our data
indicate a functional relationship among KAP, CyPB, and CsA-mediated toxicity in kidney.
 |
EXPERIMENTAL PROCEDURES |
Animals--
Six-week-old C57BL/6 and BALB/c mice were purchased
from IFFA CREDO (L'Arbescle, France). When required, males were
castrated under droperidol and midazolam anesthesia and allowed to
recover for 8 days before further treatment. Female, male, and
castrated male mice were treated for 3 days with CsA (Sandimmun,
Sandoz, Nuremberg, Germany) with intramuscular injection 15 mg/kg/day. Control mice received vehicle alone (95% olive oil, 5%
ethanol). After treatment, animals were euthanized by cervical
dislocation. Several tissues were collected and immediately frozen in
liquid N2 or embedded in OCT compound and frozen in cold
2-methylbutane.
RNA Extraction and Northern Blot Analysis--
Total RNA was
extracted from different tissues using guanidium thiocyanate-acid
phenol (13) followed by single-round mRNA extraction (Amersham
Pharmacia Biotech). mRNA was fractionated by electrophoresis
through agarose-formaldehyde gels and transferred to ZetaProbe
membranes (Bio-Rad). Membranes were hybridized at 42 °C overnight
with random primed [32P]dCTP (Amersham Pharmacia
Biotech)-labeled cDNA probes, washed following the membrane
manufacturer's instructions, and exposed to Hyperfilm (Amersham
Pharmacia Biotech). Where noted, band intensity was measured by
densitometric scanning of the resultant autoradiograph using the
Bio-Rad GS700 image densitometer and the Molecular Analyst 1.40 program.
RT-PCR and Southern Blotting--
RT-PCRs were
performed under linear conditions with respect to RNA input and the
number of amplification cycles. PCRs were determined as linear for
18-24 cycles. Primers for detecting KAP transcripts were as follows:
upper primer, 5'-TTG CCT TAA CCC TAC TAA AGC-3'; lower primer, 5'-GGA
AGT AGG GGA GAC TGG-3'. -Actin was amplified as a control of RNA
amount and integrity. Amplification products were separated on 2%
agarose gel and transferred to ZetaProbe membranes (Bio-Rad). The blots
were probed with specific [ -32P]ATP 5' end-labeled
primer corresponding to an internal sequence of the amplified product.
Hybridization, washes, and exposure were performed as above.
Production of Anti-KAP Monoclonal Antibodies--
Short peptides
pKAP1 and pKAP2, corresponding to amino acids
NH2-CPKIPLAGNPVSPTS-CONH2 and
NH2-YRGTKAPLEDY-CONH2, respectively, were selected on the
basis of their putative immunogenicity. Eight-week-old BALB/c mice were
immunized on days 0, 10, and 21 with 50-µg doses of peptides pKAP1
and pKAP2 conjugated with KLH and mixed with 50 µl of MPL+TDM
adjuvant system (Sigma-Aldrich Quimica S.A.). Three boost doses
were given at days 3, 2, and 1 prior to fusion. Splenocytes were fused
with HL-1 Friendly Myeloma-653 (Ventrex Bioventures Group) using
polyethylene glycol 1500. Fused cells were plated in 96-well
microplates and grown in selective media (39% hybridoma medium
(Life Technologies, Inc.) 39% RPMI medium, 20% fetal calf serum, 2%
hypoxanthine/aminopterin/thymidine medium, and 2 mM
glutamine). After 3 weeks, growing hybridomas were screened by ELISA
for specific antibody production.
pKAP1 and pKAP2 ELISA--
For hybridoma screening, pKAP1 and
pKAP2 were conjugated with BSA using
N-succinimidyl-3-(2-pyridyldithio)propionate (Pierce) as linker agent. Maxisorp Nunc immunoplates were coated with 2% BSA in
PBS, pH 8.3, and incubated for 4 h at room temperature. Plates
were washed three times. 100 µl of SPDP diluted at 10 µg/ml PBS, pH
8.3, were incubated at room temperature for 1 h. Plates were again
washed three times. 50 µl of freshly diluted peptides were incubated
overnight at room temperature. After three washing cycles, plates were
blocked 2 h with 5% BSA in PBS, pH 8.3. Culture supernatants were
incubated for 2 h, and bound antibodies were detected with rabbit
anti-mouse Igs alkaline phosphatase conjugate (DAKO A/S,
Copenhagen, Denmark). Immune sera and culture media were used as
positive and negative controls, respectively. Hybridomas showing a
positive reaction in pKAP1 or pKAP2-SPDP-BSA ELISA and a negative
reaction against PBS-SPDP-BSA ELISA were selected. Twenty-three
hybridomas were found to be specific for pKAP1 and 65 for pKAP2.
Anti-pKAP1 hybridomas 377-1B8 and 377-7D10 and anti-pKAP2 hybridomas
388-1D7, 3881E4, 388-1F2, 388-6F8, 388-7H9, and 388-10D1 showed high
reactivity against these peptides and were selected for cloning. Once
cloned, hybridomas were cultured in 225-cm2 flasks and left
to grow to saturation. Antibodies were purified from spent culture
media with HiTrap protein a columns (Amersham Pharmacia Biotech)
following the manufacturer's instructions.
Monoclonal Antibody Characterization--
Antibody isotyping was
performed by ELISA with monoclonal antibody-based Ig isotyping
kit (PharMingen, San Diego, CA). 388-10D1 was found to be of IgM,k
isotype. All the other hybridomas secreted IgG1,k. Hybridoma
specificity was analyzed by testing its reactivity against four
synthetic peptides of unrelated proteins: Sequence 759-770 of
v 5 integrin and sequences 1-15, 344-367, and 369-385 of hementin. These four peptides were coupled to BSA using
SPDP as linker and following the methodology as described for pKAP1 and
pKAP2 ELISA. 377-1B8 and 377-7D10 were positive against pKAP1 and
negative against pKAP2 and control peptides. Anti-KAP2 hybridomas did
not react with pKAP1 and control peptides. The monoclonal antibodies
produced by 377-1B8 and 388-1D7 were named abKAP1 and abKAP2,
respectively, and were used to identify KAP in mouse tissues.
Western Blot Analysis--
Tissues were homogenized by
N2 cavitation in RIPA buffer (DOC 0.5%, Nonidet P-40 1%,
SDS 0.1%, and protease inhibitors in 1× PBS). For Western blot
analysis, samples were normalized for protein concentration using the
Bradford assay (Bio-Rad), adjusted for equal protein levels, and
separated on 15% SDS-polyacrylamide gel electrophoresis under reducing
conditions. Proteins were transferred to a PVDF (Schleicher & Schuell)
membrane, and blots were blocked overnight at 4 °C in 5% nonfat
dried milk in PBS. Primary monoclonal antibodies (abKAP1 and abKAP2)
were diluted at 5 µg/ml in blocking buffer, and membranes were probed
for 2 h. Washes were performed following the membrane
manufacturer's instructions and secondary antibody (horseradish
peroxidase-conjugated rabbit anti-mouse, DAKO A/S) diluted
1:5000 and incubated for 1 h at room temperature. After washing,
bands were detected using the ECL+ chemiluminescence detection method
(Amersham Pharmacia Biotech) and exposed to Hyperfilm.
Immunohistochemistry--
Thin kidney sections (5 µm) were
obtained in a cryostat (Bright Instrument Company Ltd., Huntingdon,
United Kingdom). Samples were fixed in cold acetone for 10 min and
washed twice in PBS. Peroxidase activity was blocked for 10 min in
0.3% H2O2 and washed twice in PBS. Sections
were blocked in normal rabbit serum 1:10 in PBS for 10 min, and primary
antibody was diluted in PBS at 20 µg/ml. After 1 h of primary
antibody incubation, 2-min washes in PBS were performed three times.
Secondary antibody (horseradish peroxidase-conjugated rabbit
anti-mouse, DAKO A/S) diluted 1:200 in PBS was incubated for 30 min
followed by extensive washing in PBS. Finally, the sections were
incubated for 5 min with the diaminobenzidine substrate solution.
Nuclei were stained with hematoxylin-eosin solution, and slides were
dehydrated and mounted in DPX mounting medium (Agar Scientific
Ltd., Essex, United Kingdom).
Yeast Two Hybrid Library Screening--
The pBD-KAP yeast two
hybrid expression vector was constructed by PCR amplification of KAP
cDNA with specific primers (KUP2Hyb, 5'-TAT GTC GAC GCA TGA TGC TTT
TCA AGG-3', and KLOW2Hyb, 5'-TAG TCG ACG TCA GGA AGT AGG GGA GAC
TGG-3') and ligation into the SalI restriction endonuclease
site of pBD-GAL4 (Stratagene, La Jolla, CA). Male mouse kidney cDNA
library (HybriZapTM two hybrid library, Stratagene) was
cotransformed with pBD-KAP into YRG-2-competent yeast cells following
the manufacturer's instructions. A total of 6 × 103
putative interacting clones were identified by growth in selective media (Leu , Trp , His ). From
them, 10 clones were positive when screened for -gal expression.
Plasmids from these clones were purified and cotransformed again with
pBD-KAP and with control plasmids in order to confirm the interaction.
pBD-P53 and pAD-SV40 expression vectors coding for proteins P53 and
large T antigen of SV40 were used as a positive control for interaction.
Interacting Domains Identification--
Fragments of the KAP
coding sequence KAP1, KAP2, and KAP3 were generated by PCR
amplification and ligation into SalI-digested pBD-GAL4.
CyPB1, CyPB2, CyPB3 and CyPB4 fragments were also generated by PCR
amplification and ligation into
EcoRI-XhoI-digested pAD-GAL4. The primers used in
the amplification are shown in Table
I. Cloned fragments were in frame and
without mutations as determined by automatic sequencing (ABI Prism 310, Applied Biosystems, Foster City, CA). Interaction assays were performed
as described above. Liquid -gal assays were performed as previously
reported.
In Vitro Translation Assays--
KAP, CyPB, and organic anion
transporting polypeptide 1 (Oatp1) complete coding sequences
cloned in pBluescriptSK II (Stratagene) were
[35S]methionine-labeled (Amersham Pharmacia Biotech)
using the in vitro translation TNT rabbit reticulocyte
transcription/translation kit (Promega Corp., Madison, WI).
Expression and Purification of Recombinant Proteins--
JM109
bacterial cells were transformed with constructs expressing GST and
GST-KAP. Luria broth (100 ml) containing 50 µg/ml ampicillin was
inoculated with 1 ml of bacteria and incubated in an orbital shaker at
37 °C. Bacteria were grown to A600 = 0.5, induced with 0.1 mM
isopropyl-1-thio- -D-galactopyranoside, and shaken for 3 h at 37 °C. The GST-soluble protein was purified with B-PERTM reagent (Pierce). The recombinant GST-KAP
aggregates into inclusion bodies. Therefore, the insoluble protein was
solubilized with 6 M guanidine HCl and refolded with DSB
201 as previously reported (57).
Soluble lysate was conjugated with glutathione-Sepharose 4B
(Amersham Pharmacia Biotech) overnight at 4 °C. Beads were washed twice with PBS, and protein concentrations were assessed after electrophoresis on 10% polyacrylamide denaturing gels by Coomassie Blue.
GST Pull-down Assays--
For pull-down experiments, ~1 µg
of GST alone or 1 µg of GST-KAP fusion protein bound to Sepharose 4B
(Amersham Pharmacia Biotech) was used in each sample incubation. Total
volume was adjusted to 150 µl with GST buffer (5 mM
MgCl2, 150 mM KCl, 50 mM Tris-Cl,
pH 7.8, 0.5 mM EDTA, 10% glycerol, 0.1% Triton X-100, 0.1% Nonidet P-40, and protease inhibitors). Beads and in
vitro translated proteins were incubated overnight at 4 °C and
then centrifuged and washed four times in GST buffer. Beads were
resuspended in SDS loading buffer to a final volume of 150 µl and
boiled for 5 min. Proteins were electrophoresed on SDS-containing 15%
polyacrylamide gels at 40 mA, along with standard protein molecular
weight markers. Gels containing [35S]methionine-labeled
proteins were dried and exposed to Hyperfilm (Amersham Pharmacia
Biotech) overnight.
Cell Culture and Tetracycline-regulated KAP-expressing System
Establishment--
Proximal convoluted tubule cells PKSV-PCT
were cultured as described previously (14-16). Transfections were
performed using LipofectAMINE (Life Technologies Ltd.) according to the
manufacturer's instructions. Expression of GFP and GFP-KAP was
achieved by transient transfection of pEGFP-3 and pEGFP-3-KAP
(CLONTECH, Palo Alto, CA) constructs into PKSV-PCT
cells. After transfection, cells were trypsinized and seeded for
immunocytochemistry assays. In order to obtain a regulated expression
system for KAP, we used the Tet-OffTM gene expression
system (CLONTECH). PKSV-PCT cells were stably transfected with the regulator plasmid pTet-Off and selected
according to their low background and high induction levels. The more
suitable clone was selected for a second transfection with pTRE-KAP and pTK-Hyg expression plasmids, and clones resistant to hygromycin (400 µg/ml) were selected. All of them were assayed for KAP mRNA and
protein expression, and clones presenting the highest induction levels,
tight tetracycline regulation, and low background were chosen for
further studies.
Immunocytochemistry--
Cells were grown on glass slides, and
24 h later they were washed in cold PBS twice and fixed in cold
4% paraformaldehyde for 1 h followed by three 10-min PBS washes.
Aldehyde groups were blocked with 50 mM NH2Cl
for 30 min and washed for 5 min in PBS four times. Cells were
permeabilized with 0.1% saponin, 1% BSA in PBS for 30 min.
Slides were incubated for 90 min at room temperature with the primary
antibody diluted to 20 µg/ml in permeabilization buffer. Upon
washing, cells were incubated for 1 h at room temperature with the
secondary antibody diluted 1:200. After four rinses in PBS, nuclei were
stained with TO-PRO3 (Molecular Bioprobes, Eugene, OR) following the
manufacturer's instructions, and fluorescence labeling was visualized
in a Leica DM IRBE confocal microscope.
Cytotoxicity Assay--
Tet-OffTM selected clones
were grown with or without tetracycline on 96-well plates and treated
with increasing doses of CsA (0, 6.25, 9.375, 12.5, 18.75, 25, 37.5, and 50 µg/ml) for 24 h. Twelve independent wells were assayed
for each CsA concentration. Cell death was quantified using a
cytotoxicity detection kit (lactate dehydrogenase) (Roche
Diagnostics GmbH).
Statistical Analysis--
Two-way analysis of variance was
applied to investigate whether the cell death induced by CsA treatment
was affected by the expression of KAP. Planned contrasts were used to
test for differences between Tc+ and Tc- for each clone, at
different CsA concentrations. The analysis was carried out with the SAS
6.11 statistical package (SAS Institute, Cary, NC) using a general
linear model (PROC GLM), which allows for the occurrence of unbalanced designs.
 |
RESULTS |
Tissue-specific Distribution of KAP mRNA and
Identification of Its Encoded Protein--
Although tissue specificity
of the KAP mRNA has been previously reported (17), the more
sensitive RT-PCR/Southern technique was used, and distribution of KAP
mRNA was performed in a wider panel of tissues. Results shown in
Fig. 1A confirm that KAP
mRNA is exclusively expressed in the kidney and uterus of pregnant female mice from day 13 of gestation. Although not included in the
panel, and confirming previous results (7), we also observed that KAP
mRNA becomes undetectable in mouse uterus right after birth.

View larger version (99K):
[in this window]
[in a new window]
|
Fig. 1.
mRNA tissue distribution and protein
detection of KAP. A, RT-PCR/Southern blotting was
performed on a wide tissue panel, including prostate, bone, muscle,
heart, lung, cerebellum, brain, liver, submaxillary gland, testis, and
kidney. -Actin was used as an internal control. KAP mRNA was
only present in kidney. Similarly, RT-PCR/Southern blotting was
performed on uterus and placenta at different days of pregnancy.
np, nonpregnant. B, the monoclonal antibodies
abKAP1 and abKAP2 specifically recognized KAP in Western blot assays
from male mouse tissue extracts (kidney, liver, and lung), in
vitro translation product (panel 1) and recombinant
GST-KAP (panel 2). C, immunohistochemistry assays
in male mouse frozen kidney, 5-µm sections, using antibodies abKAP1
and abKAP2. Preabsorbing the antibodies with a 10-fold excess of each
antigenic peptide proved the specificity of the reactions.
|
|
Computational analysis of the KAP (GenBankTM accession
number M22810) deduced peptide sequence defines a protein of
121 amino acids in length, hydrophilic and negatively charged (2). IgG1 monoclonal antibodies abKAP1 and abKAP2 were raised against two different epitopes of KAP. They both recognized a protein with an
apparent molecular mass of 20 kDa in SDS-PAGE from mouse crude kidney extracts, which was undetectable in liver and lung (Fig. 1B) or in kidney when peptide-specific preabsorbed
antibodies were used (not shown). The antibodies were also able to
recognize the in vitro translated KAP that migrates with an
apparent size of 19 kDa in SDS-PAGE (Fig. 1B, panel 1) and
the expected 48-kDa recombinant GST-KAP, heterologously produced in
Escherichia coli (Fig. 1B, panel 2).
Immunohistochemistry assays in frozen kidney sections identified KAP in
epithelial cells of proximal convoluted tubules, which correlates with
KAP mRNA site synthesis (Fig. 1C). Antibodies preabsorbed with their corresponding antigenic peptides failed to
recognize the KAP target protein in kidney, thereby proving the
specificity of the immune reaction (Fig. 1C).
The Kidney Androgen-regulated Protein Resembles Its mRNA
Cell Distribution and Androgen Regulation--
To test whether the
cell distribution and abundance of KAP are also
androgen-dependent, Western blot and immunohistochemistry assays were performed in kidneys of intact male, female, and castrated male mice. Results in Fig. 2A
demonstrate that the relative amounts of KAP correlate with previously
reported relative mRNA levels (2), being much more abundant in
males than in females and exhibiting the lowest levels in castrated
males. Like its mRNA, KAP is expressed in S3 cells, but it is only
expressed in the S1/S2 segments of intact males (Fig.
2B).

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 2.
Kidney androgen-regulated protein expression
and distribution are under hormonal control. A, Western
blot analysis of crude kidney homogenates from male, female, and
castrated male mice (50 µg/lane) with a monoclonal antibody against
KAP. B, kidney cryosections from mice under different
hormonal status, stained with antibody abKAP1. Original magnification, × 200. Within the kidney, the protein was found in the S3 segment in
male, female, and castrated male mice. Only intact males presented
expression in the S1/S2 segment.
|
|
The Kidney Androgen-regulated Protein Specifically Interacts
with Cyclophilin B (CyPB)--
The full-length KAP cDNA was
screened against a male mouse kidney cDNA library in a yeast two
hybrid assay. One of the clones was effectively interacting with KAP to
support the permissive growth of yeast cells in selective medium and to
produce positive results in -gal assays (Fig.
3A, section 1). This clone was
identified as the mouse peptidyl-prolyl-cis-trans-isomerase
B (CyPB, GenBankTM accession number M60456).
Positive and negative interacting control proteins were also included
(Fig. 3A, section 3 and sections 2-4,
respectively). A GST pull-down assay was performed to further confirm
the KAP-CyPB interaction. Sepharose 4B-conjugated GST and GST-KAP
fusion proteins were incubated with
[35S]methionine-labeled in vitro translated
CyPB or Oatp1 proteins and extensively washed (four times) in GST wash
buffer. Eluted products shown in Fig. 3B demonstrate that
the binding capacity of CyPB for GST-KAP depends on the KAP moiety,
because GST alone is unable to bind CyPB. Similarly, KAP binds
specifically to CyPB because the Oatp1-translated product does not get
bound to KAP, thereby demonstrating the specificity of the interaction.
When CsA (10 and 25 µM) was added to the interacting
proteins, no competitive effect of the immunosuppressor was observed
when CyPB was preincubated with CsA or when the immunosuppressor was
added to the KAP-CyPB complex (data not shown).

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 3.
Interaction assays between KAP and CyPB.
A, YRG-2 yeast cells expressing both GAL4BD-KAP and
GAL4AD-CyPB were able to grow in nutritionally restrictive media (Leu-
Trp- His-) and showed -galactosidase expression. Section
1, pBD-KAP+ pAD-CyPB; section 2, pBD-KAP+ pAD-SV40;
section 3, pBD-P53+ pAD-SV40 (positive control);
section 4, pBD-P53+ pAD-CyPB. B, GST pull-down
assays. GST-KAP fusion protein or GST alone was immobilized on
Sepharose 4B and incubated with in vitro translated
[35S]methionine-labeled CyPB or Oatp1. C,
co-immunoprecipitation assays. Male mouse kidney crude extracts were
immunoprecipitated with abCyPB (lanes 2 and 4),
abKAP1 (lane 1), and abKAP2 (lane 3) and blotted
against abCyPB.
|
|
Finally, co-immunoprecipitation assays were performed on kidney crude
extracts as an in vivo demonstration of the interaction (Fig. 3C). Although we were able to recover CyPB from the
abKAP1 and abKAP2 immunoprecipitated products (Fig. 3C, lanes
1 and 3, respectively), the reverse experiment,
i.e. immunoprecipitating with the antibody against CyPB and
detecting with abKAP1 or abKAP2, gave negative results (not shown).
KAP and CyPB Co-location in Kidney Culture Cells--
Since its
identification, CyPB has been known to be part of the secretory
pathway, being present in the membrane fraction (plasma membrane,
endoplasmic reticulum, Golgi, and microsomes) (18). GFP alone and
GFP-KAP fusion construct were transfected into PKSV-PCT cells. The
GFP-KAP fusion protein was distributed around the nucleus of proximal
tubule cells following a reticular pattern consistent with an
endoplasmic reticulum location, clearly different from the distribution
observed for GFP alone (Fig.
4A). Immunocytochemistry using
anti-CyPB antibody performed on GFP-KAP-transfected cells showed
co-location of both proteins in intracellular organelles, whereas the
plasma membrane remained positive for CyPB staining only (Fig.
4B). Cells transfected with a GFP-KAP-expressing plasmid presented reduced endogenous CyPB staining at the plasma membrane level
compared with nontransfected cells (see arrows in Fig.
4B).

View larger version (71K):
[in this window]
[in a new window]
|
Fig. 4.
Co-location of GFP-KAP and CyPB.
A, PCT cells were transfected with plasmids coding
for either GFP alone or GFP-KAP fusion protein. B,
immunocytochemistry with antibodies anti-CyPB was performed on
GFP-KAP-transfected cells. Nuclei were stained with TO-PRO3.
Arrows indicate the reduced amount of CyPB labeling at the
plasma membrane of the GFP-KAP-transfected cells.
|
|
Interacting Domains between KAP and CyPB Proteins--
To
determine the domains that participate in KAP and CyPB interaction,
several KAP cDNA truncations encompassing nucleotides 1-194,
1-321, and 1-437 of the KAP open reading frame were screened against the entire coding sequence of the CyPB cDNA (Fig.
5A). Co-transformed yeast
cells carrying the KAP 1-321 and KAP 1-437 constructs were able to
grow in selective medium, whereas the KAP 1-194 construct was not
(Fig. 5B). These results indicate that the CyPB binding
capacity exhibited by KAP must be located between base pairs 194 and
321 of the cDNA, i.e. in a region of ~40 amino acids
in length, in the middle of the protein. The reverse experiment was
also performed and different CyPB overlapping fragments, such as those
from base pairs 28-231, 28-515, 231-664, and 515-664 of the
cDNA, tested against the full KAP open reading frame. As shown in
Fig. 4B, only fragments CyPB 231-664 and CyPB 515-664 were
positive. Because CyPB 28-515 was negative, the region encompassing base pairs 551-664, which codes for 37 amino acids of the C-terminal domain, is the one responsible for KAP interaction. These results were
further confirmed by the -gal liquid assays (Fig.
5C).

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 5.
Identification of the protein domains
responsible for KAP-CyPB interactions. A, protein
fragments were assayed for interaction; each fragment of KAP and CyPB
was cotransformed with the full-length cDNA of CyPB and KAP,
respectively. B, growth in selective media: pBD-P53+
pAD-SV40 (positive control) (section 1); pBD-KAP1+ pAD-CyPB
(section 2); pBD-KAP2 + pAD-CyPB (section 3);
pBD-KAP3 + pAD-CyPB (section 4); pBD-KAP + pAD-CyPB1
(section 5); pBD-KAP + pAD-CyPB2 (section 6);
pBD-KAP + pAD-CyPB3 (section 7); pBD-KAP + pAD-CyPB4
(section 8). C, -gal liquid
assay.
|
|
Effects of CsA Treatment on Kidney KAP Expression: Correlation
between the mRNA and the Protein Levels--
CsA binds to CyPB and
modulates the expression of several genes (19), some of which, but not
all, are implicated in the immune response. Because treatment with CsA
increases CyPB plasma levels (20) and CyPB has been found to interact
with KAP, we aimed to observe the effects of acute CsA treatment on KAP
kidney expression under different hormonal conditions.
Female, male, and castrated male mice were treated for 3 days with CsA
at 15 mg/kg/day by intramuscular injection and compared with
vehicle-treated mice. Results shown in Fig. 5A demonstrate a
significant 2.2- and 3.6-fold increase in
KAP/glyceraldehyde-3-phosphate dehydrogenase ratios in
CsA-treated males and females, respectively, and no effect on KAP
mRNA levels in castrated males (Fig.
6A). Western blot analysis
performed in crude extracts of counterpart kidneys revealed a
significant decrease in KAP in castrated males and females that was not
apparent in males (Fig. 6B). The hypothesis that CsA
treatment would affect KAP expression preferentially in the S3 segment
was proved by immunohistochemistry analysis in frozen kidney sections
of CsA-treated and nontreated mice. Fig. 6C demonstrates the
lower and almost nonexistent KAP levels in females and castrated males,
respectively, and the higher decrease in the protein in S3
cells than in S2 and S1 cells in males.

View larger version (116K):
[in this window]
[in a new window]
|
Fig. 6.
Effects of CsA treatment on KAP
expression. A, Northern blot assay of mouse kidney (3 µg of RNA poly(A)+/lane). Animals were injected with 15 mg/kg/day of CsA or vehicle (olive oil) for 3 days.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
cDNA hybridization in the same filters was used as an internal
control for RNA integrity and loading. Ratios between KAP-specific and
glyceraldehyde-3-phosphate dehydrogenase-specific signals are
indicated. B, Western blot assay of KAP expression in
counterpart kidneys of CsA-treated and control intact males (25 µg/lane), females (100 µg/lane), and castrated males (100 µg/lane). C, immunohistochemistry on kidneys from treated
mice. CsA diminishes KAP expression in the S3 cells in male, female,
and castrated male mice.
|
|
Production of a Stably Transfected and Tetracycline-controlled KAP
Expression System in PKSV-PCT Cells as a Model for Studying the Effects
of KAP Expression on CsA-mediated Toxicity--
KAP expression vectors
were stably transfected in the PKSV-PCT cell line, originally derived
from proximal tubules of transgenic mice carrying the large T and
little t SV40 antigens, under the control of 5' regulatory
sequences of the L-type pyruvate kinase gene that had
proved to conserve the main features of the parental cells from which
it was derived (14-16). This cell line was used to express KAP in a
controlled and inducible manner using the Tet-OffTM system
from CLONTECH.
Results in Fig. 7A are
representative of KAP mRNA levels in pTet-off regulator plasmid
stably transfected PKSV-PCT cells (clone 3-26) and in three independent
stably expressing tet-regulated pTRE-KAP clones (3-26-37, 3-26-71, and
3-26-310). Endogenous cyclophilin A (CyPA) expression levels were
determined as a control for the amount and integrity of mRNA.
Whereas results in Fig. 7A indicate that selected clones
have the ability to induce KAP mRNA in a tetracycline-dependent controlled manner, those shown in
Fig. 7B demonstrate their ability to express KAP in around
3-4 h upon tetracycline removal. Indirect immunofluorescence analysis
of expressed KAP shows a cytoplasmic reticular distribution in these cells.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 7.
KAP overexpression prevents CsA-mediated
cytotoxicity in culture proximal tubule cells. PSVK-PCT cells were
transfected with the Tet-OffTM system and assayed for
KAP-regulated expression. PCT 3-26 is transfected only with the
regulator plasmid pTet-off. PCT 3-26-37, PCT 3-26-71, and PCT 3-26-310 were obtained by stably transfecting PCT 3-26 with the plasmid
pTRE-KAP. A, RT-PCR assay with total RNA from
selected clones. Cyclophilin A (CypA) was used as an
internal control. Cells were seeded in the presence of tetracycline
(0.01 µg/ml). After extensive washing, cells were left to grow on
media with or without Tc for 24 h; RNA was then obtained, and
RT-PCR was performed. B, induction timing for KAP
expression. Cells were grown in 0.01 µg/ml of Tc. After complete Tc
removal, cultures were assayed for protein expression at different time
points (from 0 to 24 h) by Western blot assays with abKAP1. The
protein was detectable ~3-4 h post-derepression. C,
immunocytochemistry performed on clone PCT 3-26-310 with antibody
abKAP1. Staining was present in the cytoplasm, displaying a reticular
pattern. Original magnification, × 630. D, cytotoxicity
assays. Lactate dehydrogenase activity in culture media from 24 h
CsA-treated control Tet-OffTM clone PCT 3-26 and
KAP-expressing clones PCT 3-26-37, PCT 3-26-71, and PCT 3-26-310 was
measured to evaluate cell death. *, p < 0.001.
|
|
The above-described pTRE-KAP clones were used to assess the effects of
KAP expression on CsA-mediated toxicity in proximal convoluted tubule
cells, using clone 3-26 as a control. Cells were exposed to increasing
doses of CsA (from 0 to 50 µg/ml) for a period of 24 h, and
culture medium from each situation was assayed for lactate
dehydrogenase activity, as a marker of cell death. Results depicted in
Fig. 7D for clone 3-26 show the cytotoxicity levels
exhibited by these cells at increasing CsA concentrations, which were
not modified by tetracycline. Contrarily, in the three independently
generated pTRE-KAP clones, tetracycline removal significantly reduced
the toxic effects exerted by CsA (see Fig. 7D). These data
are representative of results obtained in three independent experiments
and clearly demonstrate that KAP expression protein reduces CsA
toxicity in proximal tubule cells.
 |
DISCUSSION |
Since the first description of KAP mRNA in 1979 (1),
the identification and function of its encoded protein have remained elusive. This paper reports, for the first time, KAP identification and
distribution and makes a direct attempt to gain insight into its function.
The tissue and cell specificity previously reported for KAP mRNA
(3-6, 9, 17), were further analyzed by means of the more sensitive
RT-PCR/Southern technique in a wider panel of tissues. Kidney
specificity and unique expression of KAP in the uterus during a short
period of time prior to birth, described earlier by Kasik et
al. (7), were definitively assessed in our experiments. No
functional data are available to explain the appearance of KAP mRNA
in the uterus before delivery, which, for the time being, is associated
with the estrogen sensitivity of the gene (6) and the estrogenic peak
that occurs at that time in this tissue (7).
Monoclonal antibodies raised against KAP synthetic peptides
specifically identified a protein with an apparent molecular mass of 20 kDa in SDS-PAGE that follows the same distribution and androgenic regulation as its encoding mRNA in epithelial cells of proximal convoluted tubules. Although the expected molecular mass for KAP (121 amino acids in length) is around 13 kDa, computational analysis of the
KAP-deduced peptide sequence defined a hydrophilic and negatively
charged protein (3), which might explain the delay observed in
SDS-PAGE.
As our data show KAP to be a highly specific and tightly regulated
kidney protein, we hypothesized that it might play an important role in
the homeostatic and metabolic events of proximal tubule cells. This
notion was further supported by the finding that KAP expression is
up-regulated in nephrectomized mouse kidney (21) and that its mRNA
levels significantly decrease in a mouse nephrolithiasis model (22).
Because no functional or structural domains were identified on the
KAP-deduced peptide sequence, we focused our efforts on the
identification of proteins able to interact with KAP in
vivo, which might in turn be informative of KAP function.
The major finding of the present study was that KAP interacts with
cyclophilin B, a member of the immunophilin family that exhibits
petidyl-prolyl-cis-trans-isomerase activity and the ability to bind the potent immunosuppressor CsA (23, 24). The interaction, initially observed by means of the two hybrid assay, was further confirmed by GST pull-down assays and by co-immunoprecipitation of the
KAP-CyPB complex from crude kidney extracts. We found these data very
interesting because the great clinical benefits of CsA on the
improvement of graft survival rates in solid organ transplantation are
concomitant with important undesirable nephrotoxic effects (25). The
immunosuppressive effects of CsA are known to be related to binding of
the immunophilins-CsA complex to the
calcium/calmodulin-dependent serine/threonine phosphatase
calcineurin, which blocks, in turn, its intrinsic phosphatase activity
in vitro (26). As a result, activation and translocation of
the nuclear factor of activated T cells are compromised, nuclear factor
of activated T cells-supported transcription of the interleukin 2 gene
and other cytokine genes is abolished, and T-cell activation is
inhibited. FK-506 (tacrolimus), a second T-cell immunosuppressive drug,
binds to a different cellular protein, FKBP12, and the FKBP12-FK 506 complex also binds to and inhibits calcineurin (27).
Whereas the molecular mechanisms involved in immunosuppression are well
known, those involved in nephrotoxicity are less understood. CsA exerts
its nephrotoxic effects through (i) acute changes in renal hemodynamics
(28-32) followed by irreversible striped interstitial fibrosis
(33-36), and (ii) cytotoxicity in proximal tubule cells (37-40).
In vitro model systems have revealed a site-selective action
of the cells of the proximal tubular region of the nephron (41, 42)
preferentially in epithelial cells of the S3 segment (43). Recent
reports have concluded that CsA exerts a direct toxic effect on
proximal cells by reducing DNA synthesis and cell cycle blockade (44),
which are coincidental with elevated p53 levels (45). In an
experimental model of chronic CsA nephrotoxicity, an increase in
apoptotic specific genes has been found, and it has been proposed that
increased apoptosis could explain the tubular dropout and loss of
cellularity with fibrosis (46).
Apart from these studies, the molecular mechanisms of CsA-induced
toxicity in the kidney have not been completely established, nor has it
been determined why CsA exerts its deleterious effects on the proximal
tubule and preferentially on cells of the S3 segment. The cloning of a
third mammalian cyclophilin, CyPC, which in contrast to the widely
distributed CyPA and CyPB family members was restricted to the kidney
(47) and preferentially expressed in proximal and straight tubules of
the kidney (48), suggested the possibility that CyPC could be a
mediator of the immunosuppressive and nephrotoxic actions of CsA, but
no functional data have emerged supporting the initial association
between CyPC restricted expression and CsA nephrotoxicity.
Identification of the biologically active cyclophilins to promote T
cell activation was performed in Jurkat T cells by overexpression of
different cyclophilin family members co-transfected with a phosphatase
reporter plasmid containing multiple copies of the nuclear factor of
activated T cells or nuclear factor-interleukin 2A binding sites from
the interleukin 2 enhancer (49). Both CyPA and CyPB but not CyPC
increase T cell sensitivity to CsA, demonstrating that CyPA and CyPB
are the active immunophilins able to mediate the inhibitory effects of
CsA in vivo (49). In addition to their ability to bind
calcineurin, the subcellular location of each immunophilin was shown to
be important for mediating inhibition of signal transduction by CsA. In
this regard, deletions of CyPB and CyPC domains, which change their
intracellular locations, altered their activities significantly.
Although both immunophilins are located in the ER, CyPB is associated
with a specialized part of the ER related to calcium activation events,
which permits its activity (50). It is interesting to note that the
carboxyl-terminal 37 residues of CyPB were able to confer a
significant gain in function on CyPC and that the converse construction
lowered CyPB activity (49). This region of CyPB contains the previously
characterized location signal, which could direct a foreign protein to
the specialized CyPB retention site (the calcium-containing ER
substructure or calciosome) (50). CyPC exclusion from the calciosome
may prevent it from participating in inhibition of T-cell activation.
The finding that CyPB interacts with a protein involved in calcium signaling in T cells named CAML (51) reinforces the notion that CyPB
might be involved in calcineurin activation through calcium mobilization events.
Involvement of CyPA and/or CyPB in the nephrotoxic effects of CsA has
not been assessed. Although a cyclophilin A knockout mouse has recently
been produced, nothing is known on toxicity in these
animals,3 and the question as
to which cyclophilin is relevant in nephrotoxicity remains open.
Because FK506 exhibits the same toxic effects on kidney as CsA and the
only common functional mechanism between both immunosuppressors is
calcineurin inhibition, it is accepted that nephrotoxicity will also
occur through the inhibition of this calcium
calmodulin-dependent phosphatase. Furthermore, chemical modifications of the CsA molecule aiming at eliminating its toxicity while preserving immunosuppressive effects have failed, suggesting that
both actions occur through common mechanisms (52). Taking into account
the wide tissue and cell distribution of cyclophilins, the finding that
a kidney-specific protein of the proximal tubule interacts with CyPB
(the CyP that shows the highest affinity for CsA (53) and the
highest expression levels in kidney (54)) was suggestive of a putative
new molecular pathway of CsA-mediated toxicity in this tissue.
Co-immunoprecipitation experiments and co-location within the cell
demonstrate that both proteins reside in the same subcellular
compartment. Definition of KAP and CyPB interacting domains by means of
two hybrid assays determined that the C-terminal domain of CyPB is
responsible for interaction. This result was further confirmed in the
co-immunoprecipitation assays in which we failed to detect KAP when the
immunoprecipitation was performed with an antibody that specifically
recognizes the C-terminal end of CyPB. As mentioned previously, this is
the domain responsible for CyPB sublocation to the calciosome in the ER
and the domain that is highly conserved in CyPBs from different species and not present in other cyclophilins. Interaction of KAP and CyPB was
not prevented by CsA, which concurs with the fact that domains for CsA
binding and peptidyl-prolyl-cis-trans-isomerase (PPiase) activity are in the middle of the protein
(55), and that KAP-CyPB interaction takes place at the
C-terminal domain.
Apart from being located in the endoplasmic reticulum, CyPB has
also been found in the plasma membrane and secreted to the medium (56).
Confocal microscopy performed in cultured proximal tubule cells in this
study demonstrated that endogenous CyPB in these cells is located in
the expected cellular compartments, i.e. the ER and the
plasma membrane. Interestingly, we observed that for cells transiently
transfected with a GFP-KAP fusion protein expression vector, the
overlay of KAP and CyPB shows a perfect co-location for both proteins,
and that in the presence of higher KAP levels in these transfected
cells, endogenous CyPB is located intracellularly rather than in the
plasma membrane. This observation suggests that by interacting with
CyPB, KAP might contribute to retaining this cyclophilin in the ER
compartment with possible implications on CyPB function, particularly
if we take into consideration that CsA promotes the secretion of CyPB
out of the cell (56). In a different set of experiments, we clearly
demonstrated that CsA significantly diminishes KAP levels in crude
kidney extracts, preferentially in the most sensitive site of CsA
toxicity, the S3 segment of the proximal tubules. We do not yet know
whether CsA promotes KAP degradation or its secretion out of the cell as it does for CyPB, but the fact is that KAP decreases in the kidney
in the presence of CsA. If we hypothesize that in physiological conditions KAP contributes to CyPB being retained in the ER, suboptimal KAP levels upon CsA treatment might prompt the secretion of CyPB out of
the cell, thereby lowering the CyPB reservoir in the reticulum, which
might impair calcium mobilization and, finally, calcineurin activation.
With this in mind, we aimed at observing the effect of KAP
overexpression on CsA-mediated toxicity in PKSV-PCT cells. It was remarkable to observe that in three independently stably transfected clones, selected by their ability to induce KAP expression in a
tetracycline-dependent manner, CsA-induced toxicity was
significantly diminished when KAP expression was permitted. It is
important to point out that because the cells were stably rather than
transiently transfected, the levels of KAP expression were not much
higher than the basal levels, and consequently, the effect of KAP
expression was highly relevant in diminishing toxicity. Although
overexpression and knocking out of the KAP gene in whole animals will
be required to demonstrate that KAP may protect against CsA toxicity
in vivo, the experiments presented in this paper are
significant because they relate the presence of KAP to CsA toxicity in
a system isolated from the multiple and complex interactions that occur
in the kidney upon treatment with the immunosuppressive drug. This cell
system will be a valuable model for gaining further insight into the physiological role of KAP in the kidney and its relevance in
CsA-mediated toxicity in proximal tubule cells. The concept that KAP
could be involved in processes that end in calcium mobilization will be
studied further, and it will be of great interest to determine whether the up-regulation that KAP mRNA exhibits in the uterus of
pregnant females is involved in calcium mobilization, as this is an
important step in the excitability of uterine smooth muscle cells
during delivery.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Benjami Piña for
advice in the two hybrid assays, Dr. Enrique Querol for computational
analysis, Dr. David Andreu for peptide synthesis, Dr. Leonardo Pardo
for statistical analysis, Dr. J. L. Tovar for encouragement and
advice, and Christine O'Hara for English corrections. We deeply thank
Dr. A. Vandewalle for providing us with the PKSV-PCT cells.
 |
FOOTNOTES |
*
This work was supported by Grant PM97-0095 from the
Ministerio de Educacion y Cultura, Programa Sectorial de
Promoción General del Conocimiento. This work has been
awarded the Iñigo Alvarez de Toledo prize for the basic research
in Nephrology (Edition XII, 2000).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. Tel.:
34-93-4894061; Fax: 34-93-4894064; E-mail:
meseguer@hg.vhebron.es.
Published, JBC Papers in Press, April 25, 2001, DOI 10.1074/jbc.M102916200
2
M. Soler, E. Solé, A. Menoyo, H. Hardy, J. F. Catterall, A. Vandewalle, and A. Meseguer,
unpublished results.
3
J. Luban, personal communication.
 |
ABBREVIATIONS |
The abbreviations used are:
KAP, kidney
androgen-regulated protein;
CsA, cyclosporine A;
CyP, cyclophilin;
GFP, green fluorescent protein;
GST, glutathione S-transferase;
abKAP, monoclonal antibody against KAP;
RT, reverse
transcription;
PCR, polymerase chain reaction;
ELISA, enzyme-linked
immunosorbent assay;
Tc, tetracycline;
BSA, bovine serum albumin;
PBS, phosphate-buffered saline;
-gal, -galactosidase;
Oatp1, organic anion transporting polypeptide 1;
ER, endoplasmic reticulum;
SPDP, N-succinimidyl-3-(2-pyridyldithio) propionate.
 |
REFERENCES |
| 1.
|
Toole, J. J.,
Hastie, N. D.,
and Held, W. A.
(1979)
Cell
17,
441-448
|
| 2.
|
Meseguer, A.,
and Catterall, J. F.
(1987)
Mol. Endocrinol.
1,
535-541
|
| 3.
|
Meseguer, A.,
Watson, C. S.,
and Catterall, F. J.
(1989)
Mol. Endocrinol.
3,
962-967
|
| 4.
|
Meseguer, A.,
and Catterall, J. F.
(1990)
Mol. Endocrinol.
4,
1240-1248
|
| 5.
|
Solé, E.,
Calvo, R.,
Obregón, M. J.,
and Meseguer, A.
(1994)
Endocrinology
135,
2120-2129
|
| 6.
|
Meseguer, A.,
and Catterall, J. F.
(1992)
Mol. Cell. Endocrinol.
89,
153-162
|
| 7.
|
Kasik, J. W.,
and Rice, E. J.
(1993)
Mol. Cell. Endocrinol.
90,
239-242
|
| 8.
|
Runic, R.,
Zhu, L.-J.,
Crozat, A.,
Bagchi, M. K.,
Catterall, J. F.,
and Bagchi, I. C.
(1995)
Endocrinology
137,
729-737
|
| 9.
|
Solé, E.,
Calvo, R.,
Obregón, M. J.,
and Meseguer, A.
(1996)
Mol. Cell. Endocrinol.
119,
147-159
|
| 10.
|
El-Meanawy, M. A.,
Schelling, J. R.,
Pozuelo, F.,
Churpek, M. M.,
Ficher, E. K.,
Iyengar, S.,
and Sedor, J. R.
(2000)
Am. J. Physiol. Renal Physiol.
279,
F383-F392
|
| 11.
|
Virlon, B.,
Cheval, L.,
Buhler, J.-M.,
Billon, E.,
Doucer, A.,
and Elalouf, J.-M.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
15286-15291
|
| 12.
|
Takenaka, M.,
Imai, E.,
Xaneko, T.,
Ito, T.,
Moriyama, T.,
Yamauchi, A.,
Hori, M.,
Kawamoto, S.,
and Okubo, K.
(1998)
Kidney Int.
53,
562-572
|
| 13.
|
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159
|
| 14.
|
Cartier, N.,
Lacave, R.,
Vallet, V.,
Hajeje, J.,
Hellio, R.,
Rojine, S.,
Drinpault, E.,
Cluzead, F.,
Briand, P.,
and Kahn, A.
(1993)
J. Cell Sci.
104,
695-704
|
| 15.
|
Lacave, R.,
Bens, M.,
Cartier, N.,
Vallet, V.,
Rojine, S.,
Drinpault, E.,
Kahn, A.,
and Vandewalle, A.
(1993)
J. Cell Sci.
104,
705-712
|
| 16.
|
Ouar, Z.,
Solé, E.,
Bens, M.,
Rafestin-Oblin, M. E.,
Meseguer, A.,
and Vandewalle, A.
(1998)
Kidney Int.
53,
59-66
|
| 17.
|
Melià, M. J.,
Bofill, N.,
Hubank, M.,
and Meseguer, A.
(1998)
Endocrinology
139,
688-695
|
| 18.
|
Hasel, K. W.,
Glass, J. R.,
Godbout, M.,
and Sutcliffe, J. G.
(1991)
Mol. Cell. Biol.
11,
3484-3491
|
| 19.
|
Ruhlmann, A.,
and Nordheim, A.
(1997)
Immunobiology
198,
192-206
|
| 20.
|
Denys, A.,
Allain, F.,
Masy, E.,
Dessaint, J.-P.,
and Spik, G.
(1998)
Transplantation
65,
1076-1084
|
| 21.
|
Zhang, H.,
Wada, J.,
Kanwar, Y. S.,
Tsuchiyama, Y.,
Hiragushi, K.,
Hida, K.,
Shikata, K.,
and Makino, H.
(1999)
Kidney Int.
56,
549-558
|
| 22.
|
Wang, L.,
Raikwar, N.,
Deng, L.,
Yang, M.,
Liang, L.,
Shao, C.,
Evan, A. P.,
Stambrook, P. J.,
Sahota, A.,
and Tischfield, J. A.
(2000)
Kidney Int.
58,
528-536
|
| 23.
|
Handschumacher, R. E.,
Harding, M. W.,
Rice, J.,
Drugge, R. J.,
and Speicher, D. W.
(1984)
Science
226,
544-547
|
| 24.
|
Harding, M. W.,
Handschumacher, R. E.,
and Speicher, D. W.
(1986)
J. Biol. Chem.
261,
8547-8555
|
| 25.
|
Bennet, W. M.,
Burdmann, E.,
Andor, T.,
Elzinga, L.,
and Franceschini, N.
(1994)
Miner. Electrolyte Metab.
20,
214-220
|
| 26.
|
Liu, J.,
Farmer, J. D.,
Lane, W. S.,
Friedman, J.,
Weissman, I.,
and Schreiber, S. L.
(1991)
Cell
66,
807-815
|
| 27.
|
Schreiber, S. L.,
and Crabtree, G. R.
(1992)
Immunol. Today
13,
136-142
|
| 28.
|
Takeshi, F. A.,
Burdmann, E. A.,
and Bennett, W. M.
(1997)
Semin. Nephrol.
17,
34-45
|
| 29.
|
Ader, J.-L.,
and Rostaing, L.
(1998)
Curr. Opin. Nephrol. Hypertens.
7,
539-545
|
| 30.
|
Mattos, A. M.,
Olyaei, A. J.,
Pharm, D.,
and Bennett, W. M.
(2000)
Am. J. Kidney Dis.
35,
333-346
|
| 31.
|
Navarro-Antolin, J.,
Rey-Campos, J.,
and Lamas, S.
(2000)
J. Biol. Chem.
275,
3075-3080
|
| 32.
|
Buetler, T. M.,
Cottet-Maire, F.,
Krauskopf, A.,
and Ruegg, U. T.
(2000)
Trends Pharmacol. Sci.
21,
288-290
|
| 33.
|
Kopp, J. B.,
and Klotman, P. E.
(1990)
J. Am. Soc. Nephrol
1,
162-179
|
| 34.
|
Shihab, F. S.,
Andoh, T. F.,
Tanner, A. M.,
Noble, N. A.,
Franceschini, N.,
and Bennett, W. M.
(1996)
Kidney Int.
49,
1141-1151
|
| 35.
|
Wolf, G.,
Thaiss, F.,
and Stahl, R. A. K.
(1995)
Transplantation
60,
237-241
|
| 36.
|
Shihab, F. S.,
Bennett, W. M.,
Tanner, A. M.,
and Andoh, T. F.
(1997)
Kidney Int.
52,
660-673
|
| 37.
|
von Willebrand, E.,
and Hayry, P.
(1983)
Lancet
2,
189-192
|
| 38.
|
Suzuki, S.,
Oka, T.,
Okhuma, S.,
and Kuriyama, K.
(1987)
Transplantation
44,
363-368
|
| 39.
|
Myers, B. D.,
Ross, J.,
Newton, L.,
Leutscher, J.,
and Perloth, M.
(1984)
N. Engl. J. Med.
331,
699-705
|
| 40.
|
Anderson, R.,
Van Rensburg, C. E.,
and Myer, M. S.
(1994)
Toxicol. Appl. Pharmacol.
125,
176-183
|
| 41.
|
Healy, E.,
Clarke, H.,
O'Connell, C.,
and Ryan, M. P.
(1994)
Br. J. Pharmacol.
112,
142. P
|
| 42.
|
Healy, E.,
Clarke, H.,
Lally, C.,
and Ryan, M. P.
(1995)
J. Am. Soc. Nephrol.
6,
999
|
| 43.
|
Mihatsch, M. J.,
Ryffel, B.,
Hermle, M.,
Brunner, F. P.,
and Thiel, G.
(1986)
Clin. Nephrol.
25,
S2-S8
|
| 44.
|
Healy, E.,
Dempsey, M.,
Lally, C.,
and Ryan, M. P.
(1998)
Kidney Int.
54,
1955-1966
|
| 45.
|
Healy, E.,
Lally, C.,
and Ryan, M. P.
(1999)
Kidney Int.
56,
1254-1257
|
| 46.
|
Shihab, F. S.,
Andoh, T. F.,
Tanner, A. M.,
Hong, Y.,
and Bennett, W. M.
(1999)
Kidney Int.
56,
2147-2159
|
| 47.
|
Friedman, J.,
and Weissman, I.
(1991)
Cell
68,
799-806
|
| 48.
|
Otsuka, M.,
Terada, Y.,
Yang, T.,
Nonoguchi, H.,
Tomita, K.,
and Marumo, F.
(1994)
Kidney Int.
45,
1340-1345
|
| 49.
|
Bram, R. J.,
Hung, D. T.,
Martin, P. K.,
Schreiber, S. L.,
and Crabtree, G. R.
(1993)
Mol. Cell. Biol.
13,
4760-4769
|
| 50.
|
Arber, S.,
Krause, K. H.,
and Caroni, P.
(1992)
J. Cell Biol.
116,
113-125
|
| 51.
|
Bram, R. J.,
and Crabtree, G. R.
(1994)
Nature
371,
355-358
|
| 52.
|
Sigal, N. H.,
Dumont, F.,
Durette, P.,
Siekirka, J. J.,
Peterson, L.,
Rich, D. H.,
Dunlap, B. E.,
Staruch, M. J.,
Melino, M. R.,
and Koprak, S. L.
(1991)
J. Exp. Med.
173,
619-628
|
| 53.
|
Schneider, H.,
Charara, N.,
Schmitz, R.,
Wehrli, S.,
Mikol, V.,
Zurini, M. G. M.,
Quesniaux, V. F. J.,
and Movva, N. R.
(1994)
Biochemistry
33,
8218-8224
|
| 54.
|
Kainer, D. B.,
and Doris, P. A.
(2000)
Hypertension
35,
958-964
|
| 55.
|
Mikol, V.,
Kallen, J.,
and Walkinshaw, M. D.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
5183-5186
|
| 56.
|
Price, E. R.,
Jin, M.,
Lim, D.,
Pati, S.,
Walsh, C. T.,
and McKeon, F. D.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
3931-3935
|
| 57.
|
Goldberg, M. E.,
Expert-Bezancon, N.,
Vuillard, L.,
and Rabilloud, T.
(1996)
Fold. Des.
1,
21-27
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Puigmule, J. Lopez-Hellin, G. Sune, O. Tornavaca, S. Camano, A. Tejedor, and A. Meseguer
Differential proteomic analysis of cyclosporine A-induced toxicity in renal proximal tubule cells
Nephrol. Dial. Transplant.,
April 15, 2009;
(2009)
gfp149v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Tornavaca, G. Pascual, M.L. Barreiro, M.T. Grande, A. Carretero, M. Riera, E. Garcia-Arumi, B. Bardaji, M. Gonzalez-Nunez, M.A. Montero, et al.
Kidney Androgen-Regulated Protein Transgenic Mice Show Hypertension and Renal Alterations Mediated by Oxidative Stress
Circulation,
April 14, 2009;
119(14):
1908 - 1917.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Teixido, M. Soler, N. Rivera, J. Bernues, and A. Meseguer
CCAAT/Enhancer Binding Protein-Mediated Role of Thyroid Hormone in the Developmental Expression of the Kidney Androgen-Regulated Protein Gene in Proximal Convoluted Tubules
Mol. Endocrinol.,
February 1, 2006;
20(2):
389 - 404.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Dou, S. Thompson-Jaeger, S. J. F. Laulederkind, J. W. Becker, J. Montgomery, E. Ruiz-Bustos, D. L. Hasty, L. R. Ballou, P. S. Eastman, B. Srichai, et al.
Defective expression of Tamm-Horsfall protein/uromodulin in COX-2-deficient mice increases their susceptibility to urinary tract infections
Am J Physiol Renal Physiol,
July 1, 2005;
289(1):
F49 - F60.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Malstrom, O. Tornavaca, A. Meseguer, A. F. Purchio, and D. B. West
The Characterization and Hormonal Regulation of Kidney Androgen-Regulated Protein (Kap)-Luciferase Transgenic Mice
Toxicol. Sci.,
June 1, 2004;
79(2):
266 - 277.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. G. Tzortzaki, D. Glass, M. Yang, A. P. Evan, S. B. Bledsoe, P. J. Stambrook, A. Sahota, and J. A. Tischfield
Gender- and Age-dependent Changes in Kidney Androgen Protein mRNA Expression in a Knockout Mouse Model for Nephrolithiasis
J. Histochem. Cytochem.,
December 1, 2002;
50(12):
1663 - 1669.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|